Hims & Hers Health Inc. (HIMS) shares surged 15.14% intraday on Wednesday after the company announced its plans to introduce at-home lab testing through its platform, following the acquisition of at-home lab testing facility Trybe Labs.

The acquisition of Sigmund NJ LLC, marketed as Trybe Labs, will allow Hims & Hers to support at-home blood draws and more comprehensive whole body testing. This move is expected to broaden the company's ability to offer a wide range of personalized treatments, supplements, and medications, as well as accelerate the expansion into new high-impact clinical categories like low testosterone, perimenopausal, and menopausal support.

Customers will be able to learn more about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health through at-home blood tests. Providers on the platform will then use this information to determine personalized treatment plans most appropriate for each patient. The company also plans to leverage de-identified lab data to enhance its AI developments, including MedMatch by Hims & Hers, aiming to deliver an AI-powered healthcare experience tailored to individual needs.